Ascendis Pharma A (ASND) Net Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted Net Margin of 256.45% for Q1 2026, up 3236.31% sequentially from 8.18% in Q4 2025, and up 35025.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) Net Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Net Margin for 13 years, with the latest figure at 256.45% in Q1 2026.
- Quarterly Net Margin rose 35025.0% year-over-year to 256.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56.0% (up 4006.0% YoY) and the FY2025 annual result came in at 32.16%, up 6102.0% from the prior year.
- Net Margin grew to 256.45% in Q1 2026 per ASND's latest filing, from 8.18% in the prior quarter.
- Over five years, Net Margin peaked at 1837.99% in Q1 2022 and troughed at 1119.44% in Q3 2022.
- A 5-year average of 164.39% and a median of 136.65% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 1181574 bps in 2022, then jumped 145716 bps in 2023.
- Over 5 years, Net Margin stood at 905.96% in 2022, then jumped by 97 bps to 29.19% in 2023, then surged by 57 bps to 12.41% in 2024, then surged by 34 bps to 8.18% in 2025, then surged by 3236 bps to 256.45% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 256.45%, 8.18%, and 29.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn | 1.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43% |
| Mar 31, 2026 | 1.24% |
| Dec 31, 2025 | -13.56% |
| Sep 30, 2025 | -0.74% |
| Jun 30, 2025 | -0.89% |
| Mar 31, 2025 | -0.07% |
| Dec 31, 2024 | 0.48% |
| Sep 30, 2024 | 0.27% |
| Jun 30, 2024 | 0.04% |
| Mar 31, 2024 | 0.07% |
| Dec 31, 2023 | -1.09% |
| Sep 30, 2023 | 1.19% |
| Jun 30, 2023 | -2.14% |
| Mar 31, 2023 | -2.34% |
| Dec 31, 2022 | 9.66% |
| Sep 30, 2022 | -14.43% |
| Jun 30, 2022 | -12.29% |
| Mar 31, 2022 | 6.22% |
| Dec 31, 2021 | -448.58% |
| Sep 30, 2021 | 91.28% |